📑 What This Document Is 📄

This filing is a material disclosure (an 8-K) announcing significant scientific progress for Prelude Therapeutics. It serves to update investors and the public on the impressive preclinical data generated for the company's lead drug candidate, PRT13722. 👉 Essentially, Prelude is sharing proof that their drug candidate showed strong results in lab models, bringing them closer to filing for human clinical trials.

🔬 The Core Science: What is PRT13722? 🧬

Prelude Therapeutics is focused on precision oncology, which means developing highly targeted medicines for specific types of cancer. Their lead drug, PRT13722, is designed for the treatment of hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2-) breast cancer.

• Targeting Mechanism: PRT13722 is a "KAT6A degrader." This is complex, so think of it this way: instead of blocking a faulty switch in the cancer cell (like a traditional drug), PRT13722 essentially marks the faulty switch (the KAT6A protein) for destruction by the cell itself. This is a "highly differentiated, first-in-class, orally bioavailable, potent and highly-selective" approach.
• What it targets: The drug specifically targets KAT6A, which is an emerging and important molecular target in ER+ breast cancer.
• Advantage over peers: Prelude claims that by targeting only KAT6A, the drug causes a more complete disruption of the regulatory pathways than drugs that inhibit both KAT6A and KAT6B, leading to better efficacy.

🧑‍🔬 Preclinical Efficacy and Safety Results 📊

The biggest takeaway from the filing is the strong data presented at the AACR Annual Meeting 2026. These studies used "xenograft models"—lab models that use human tumor cells grown in animals, simulating cancer progression.

• Powerful Tumor Regression: PRT13722 was shown to drive durable complete tumor regressions in HR+/HER2- xenograft models. These results were observed even in cells that were resistant to previous endocrine therapy (ET).
• Combination Potential: The drug showed promise not just alone (monotherapy) but also when combined with standard-of-care treatments, such as ET, CDK4/6 inhibitors, and PI3Kα inhibitors. This suggests it could be a key component of future multi-drug regimens.
• Safety Profile: Critically, the preclinical data indicates an improved hematological safety profile compared to a drug called prifetrastat. This is a major safety signal that could allow it to be combined with other existing treatments.

🗓️ Development Milestones and Future Plans 🚀

The company provided clear timelines for its development, outlining what steps they plan to take next to move from the lab to human patients.

• IND Filing Timeline: Prelude remains on track to file an Investigational New Drug (IND) application for PRT13722 in the middle of 2026.
  • Why this matters: Filing an IND application is the critical step where the company submits comprehensive data to the FDA to get permission to test the drug in humans.
• Clinical Trial Start: Pending regulatory clearance, the company plans to initiate Phase 1 clinical trials in the second half (2H) of 2026.
  • Why this matters: This sets concrete expectations for readers and investors about the company's near-term goals and milestones.

💬 Expert Commentary and Scientific Insights 🎤

The filing includes commentary from key executives and academic advisors, which helps frame the potential impact of the drug.

• Chief Scientific Officer (Peggy Scherle, Ph.D.): Scherle stated that the data "further strengthen our hypothesis that developing a highly selective degrader specifically targeting KAT6A has the potential for further improvements of efficacy and importantly an improved hematological safety profile."
  • 👉 Interpretation: She is highlighting that the two major breakthroughs—improved safety and improved efficacy—are what make this drug potentially game-changing.
• Clinical Advisor (Edith A. Perez, M.D.): Dr. Perez emphasized that "There remains a significant unmet need for new treatment options to further improve the standard of care in breast cancer."
  • 👉 Interpretation: This statement validates the entire field of research, reinforcing that the market is ripe for novel, highly effective treatments like PRT13722.
• Scientific Presentation (Koichi Ito, Ph.D.): At the AACR Meeting, Koichi Ito provided a detailed lecture on "Targeted Protein Degrader-Antibody Conjugates (DACs)," which shows the sophisticated nature of the advanced technology Prelude is leveraging.

🏢 Company Overview and Pipeline Scope 🌐

Prelude is a specialized precision oncology company. They are leveraging their expertise in targeted protein degradation to create the next generation of drugs.

• Technological Focus: The company develops "degraders," which are advanced molecules that instruct the body to break down specific problematic proteins.
• Key Pipeline Focus: Their pipeline includes highly selective KAT6A degraders (like PRT13722) and JAK2V617F mutant selective inhibitors.
• Goal: Their mission is to use these new approaches to deliver "transformative potential for patients" in areas with high unmet medical needs.

📞 Investor and Contact Information 📧

If you need to follow up on this material, the filing provides clear contact channels for investor relations.

• Robert A. Doody, Jr.
  • Senior Vice President, Investor Relations
  • Phone: 484.639.7235
  • Email: [email protected]
• Robert Doody
  • SVP, Investor Relations
  • Email: [email protected]

🧠 The Analogy 💡

Imagine a complex machine (the cancer cell) that has a specific, vital faulty component (the KAT6A protein) that is causing it to malfunction. Traditional drugs are like generalized blunt tools—they might knock out several parts, but they can also damage healthy parts of the machine (the side effects). PRT13722, however, is like a highly specific molecular garbage disposal unit. It doesn't just knock out the component; it specifically tags only the malfunctioning KAT6A protein for the cell's internal cleanup crew, restoring function while minimizing damage to healthy cell parts.

🧩 Final Takeaway 🌟

Prelude Therapeutics presented highly promising preclinical data for PRT13722, positioning it as a first-in-class, potent, and safe treatment for HR+/HER2- breast cancer. The company remains on a clear path, targeting an IND filing by mid-2026 and Phase 1 trials in the second half of 2026.